**Excerpt:** President Trump is set to sign an executive order to initiate federal research on ibogaine, a psychedelic drug used abroad for PTSD treatment.
Key Points
– President Trump will sign an executive order to explore the use of ibogaine for PTSD.
– Ibogaine is currently illegal in the U.S. and classified as a Schedule I substance.
– The order aims to facilitate federal funding for research on ibogaine’s safety and effectiveness.
– Texas has allocated $50 million for ibogaine research, reflecting growing interest in its potential.
– Concerns exist regarding ibogaine’s safety, particularly its risks to heart health.
Overview of the Executive Order
The White House is preparing to issue an executive order that will signal the Trump administration’s willingness to investigate ibogaine, a psychedelic derived from a shrub native to Africa. This compound is used in some countries to treat conditions such as depression, anxiety, addiction, and post-traumatic stress disorder (PTSD).
Background on Ibogaine
Ibogaine is currently classified as a Schedule I drug in the United States, meaning it is viewed as having no accepted medical use and a high potential for abuse. As a result, many Americans seeking treatment have traveled to unregulated clinics in Mexico or the Caribbean to access the drug.
Purpose of the Executive Order
The forthcoming executive order aims to pave the way for federal funding to assess ibogaine’s effectiveness in treating PTSD and traumatic brain injuries, particularly among veterans. Sources indicate President Trump plans to sign this order within the week.
Previous Research and Developments
Discussions were sparked by a 60 Minutes segment featuring U.S. veterans who sought relief from intrusive memories through a psychedelic retreat in Mexico. In Texas, Governor Greg Abbott has advocated for ibogaine research, approving $50 million in funding for studies.
Safety Concerns
Despite interest in ibogaine’s potential benefits, significant safety concerns remain. The Drug Enforcement Administration (DEA) has classified ibogaine with substances like heroin and ecstasy. The most critical risk associated with ibogaine is its impact on heart health, with studies indicating it can cause dangerous heart rhythm disturbances.
Research is still in preliminary stages, with only one double-blind, placebo-controlled trial completed, and further trials are beginning. While some studies report ibogaine may alleviate withdrawal symptoms and cravings, the risk of toxicity and fatality is a significant concern.
Conclusion
The Trump administration’s move to examine ibogaine could mark a significant shift in the approach to psychedelic treatments for PTSD, opening doors for further research while also highlighting the need for rigorous safety evaluations.
Leave a Reply